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ABSTRACT. Background: Parkinson’s disease is frequently omitted as a cause of 
death from death certificates. A limitation of previous studies that attempted to 
assess the validity of death certificates is that population-dwelling cases, with milder, 
undiagnosed Parkinson’s disease were likely excluded. As a result, those studies 
likely overestimated the validity of death certificates because they did not include 
these milder cases. We assessed the validity of death certificates in a prospective 
population-based study (NEDICES), which includes previously undiagnosed 
Parkinson’s disease cases detected during the assessment. 
Methods: 3,926 community-dwelling elderly subjects with and without Parkinson’s 
disease were followed during a median of 12.6 years, after which the death 
certificates of those who died were examined. We calculated the proportion of cases 
of clinically diagnosed Parkinson’s disease for whom a diagnosis of Parkinson’s 
disease was certified as the basic cause of death on death certificates. 
Results: 1,791 (45.6%) of 3,926 participants died over a median follow-up of 7.1 
years, including 82 (73.9%) deaths among 111 participants with Parkinson’s disease. 
Parkinson’s disease was rarely certified as the basic cause of death (14.6%). 
Gender, disease stage and the period during which the study was conducted (i.e., 
1994 to 2007) did not influence the likelihood that Parkinson’s disease would be 
reported. 
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Conclusions: Our findings reinforce the notion that the reporting of Parkinson’s 
disease on death certificates remains poor. This suggests a lack of awareness of the 




The burden of neurodegenerative diseases in high income countries is 
increasing, as the mean age of these populations increases. Parkinson’s disease 
(PD) is one of the most common neurodegenerative disorders. With an increase in 
the prevalence of older people in recent decades, epidemiological and clinical 
information on PD becomes even more essential.[1] Two of the most relevant public 
health indicators are mortality rate and the cause of death. Death certificates have 
often been used as a source of data in order to understand the incidence, 
prevalence, and the mortality of PD,[2-6] as well as the causes of death associated 
with PD.[7, 8] However, the utility of such data may be limited.[9, 10] Often, death 
certificates do not accurately reflect the mortality of PD.[9] Previous studies have 
shown that PD is frequently omitted from the death certificate, even in cases with 
clear and long-standing PD.[9, 11-16]  
A limitation of previous studies is that population-dwelling cases may not have 
been included. Therefore, it is likely that those studies overestimated the validity of 
death certificates because they did not include these milder cases.[9, 11-16] Our aim 
was to assess the validity of death certificates in a prospective population-based 
study (NEDICES), which includes previously undiagnosed Parkinson’s disease 




Data for these analyses were derived from the Neurological Diseases in 
Central Spain (NEDICES) study, a longitudinal, population-based survey of the 
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prevalence, incidence, mortality, and determinants of major age-associated 
conditions of the elderly, including PD, essential tremor, stroke, and dementia.[17-27] 
Detailed accounts of the study population and sampling methods have been 
published.[28-30] 
The survey area consisted of three communities: Margaritas (approximately 
14,800 inhabitants), a working-class neighborhood in Getafe (Greater Madrid); Lista 
(approximately 150,000 inhabitants), a professional-class neighborhood in Salamanca 
district (Central Madrid), and Arévalo (approximately 9,000 inhabitants), the 
agricultural zone of Arévalo County (125 km northwest of Madrid). Up-to-date lists of 
residents were generated from population registers. In each community, survey 
eligibility was restricted to residents aged 65 years or older who were present there on 
December 31, 1993, or during 6 or more months of 1993. Eligible persons who had 
moved away from the survey area were not traced. In Margaritas and Arévalo, every 
eligible subject was to be screened. Because of the large number of elderly residents 
in Lista, proportionate stratified random sampling was used to select subjects for 
screening. All procedures were approved by the ethical standards committees on 
human experimentation at the University Hospitals “12 de Octubre” (Madrid) and “La 
Princesa” (Madrid). Written (signed) informed consent was obtained from all enrollees. 
 
Study evaluation 
Briefly, at the time of their baseline assessment (1994–1995), 5,278 elderly 
subjects were interviewed using a 500-item screening questionnaire that assessed 
demographic factors and medical conditions. The face-to-face interview included 
data collection on demographics, current medications (including drugs that affect the 
central nervous system), and medical conditions.  
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A short form of the questionnaire was mailed to subjects who declined or were 
unavailable for face-to-face interview, or telephone screening. This form collected data 
on demographic characteristics, several neurological disorders (essential tremor, 
stroke, dementia, and parkinsonism), current medications, and also requested the 
name of the subjects’ family doctor. 
The screening protocol for parkinsonism included three questions: (1) previous 
diagnosis of PD or parkinsonism, (2) complaint of tremor, (3) complaint of 
slowness.[17, 18]  Participants were considered to have screened positive for 
parkinsonism if they responded positively to one or more question. Persons who 
screened positive for PD underwent a neurological examination, which was comprised 
of a general neurological examination and the motor portion of the Unified Parkinson’s 
Disease Rating Scale (UPDRS).[31] The neurological examination was performed by 
one of eight senior neurologists who met at the inception of the study to establish 
standardized methods to perform and interpret the examination (J. B-L, F. B-P., and 
see http://www.ciberned.es/estudio-nedices). For subjects who could not be 
examined, medical records were obtained from their general practitioners, from in-
patient hospitalizations, and from neurological specialists (if they had visited one). We 
defined parkinsonism based on four cardinal signs: resting tremor, rigidity, 
bradykinesia, and impaired postural reflexes.[17, 18]  Parkinsonism was diagnosed 
when at least two signs were present in a subject not receiving anti-parkinsonian 
therapy, or when at least one sign was present in a patient specifically treated.[17, 18] 
Among subjects fulfilling these criteria, the etiologic subgroups were defined as 
follows: 
 Drug-induced parkinsonism was defined as an entity following the use of 
antidopaminergic drugs in the six months preceding onset of symptoms, along with a 
 9 
previously negative history for the parkinsonian signs. The diagnoses were confirmed 
if the parkinsonian symptoms disappeared or subsided six months after stopping the 
drug, whenever it was possible.[17, 18] 
Vascular parkinsonism was defined by the presence of at least two of the 
following findings: history of repeated strokes with abrupt onset and stepwise 
progression of parkinsonism features, hypertension, emotional incontinence and 
pseudobulbar palsy, broad-based rigid gait, and widespread pyramidal signs.[17, 18] 
Parkinsonism with associated features, or due to other etiologies, such as 
nervous system infection, severe head trauma, brain tumor, dementia, or other 
neurological diseases that possibly affected the basal ganglia, was defined by routine 
clinical diagnosis.[17, 18] This type of parkinsonism also included Parkinson-plus 
syndromes.[17, 18]  
Subjects were diagnosed as having definite PD or idiopathic parkinsonism after 
the exclusion of all other possible causes of parkinsonism. Unspecified parkinsonism 
was that for which clinical information was insufficient to reach an etiologic 
classification. A Hoehn and Yahr stage was assigned to each case.[32] 
During the second (i.e., follow-up) evaluation (1997–1998), the same methods 
were used. Follow-up data on death were collected until May 1, 2007. The date of 
death was obtained from the National Population Register of Spain (Instituto Nacional 
de Estadística). In all Spanish communities, all deceased individuals receive the death 
certificate, completed by a doctor, at the time of death. In accordance with the 
recommendations of the World Health Organization, the classification of causes of 
death is based on the basic cause of death.[33] This is defined as the illness or injury 
which started the chain of pathological events which directly led to death.[33] The 
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certificate is then sent to the local authority in the municipality where the person had 
been living, and the information is collected in the National Register. The cause of 
death (using the International Classification of Diseases - ICD- 9th Revision for deaths 
occurred prior to 1999, and the ICD 10th Revision for deaths occurring thereafter) was 
divided into six primary categories: dementia, cerebrovascular disorders, 
cardiovascular disorders (pulmonary embolism, congestive heart failure, myocardial 
infarction, heart or aortic rupture, and asystole), respiratory diseases, cancer, and 
other causes (infections, trauma, genitourinary or gastrointestinal disorders).[33] 
 
Statistical analyses 
Data analyses were performed in SPSS Version 21.0 (SPSS, Inc., Chicago, 
IL). Unadjusted (bivariate) analyses were performed using the t test to compare 
mean ages and chi-square tests to determine associations between categorical 
variables. 
We calculated the proportion of cases of clinically diagnosed PD for whom a 
diagnosis of PD was listed as the primary cause of death on the death certificate. To 
further determine whether PD was more likely to be certified in distinct subgroups of 
PD patients, we characterized the sample by age, gender, and PD stage. 
To identify the subject characteristics that were associated with having PD reported 
on death certificates, we performed a stepwise multiple logistic regression model 
with the dependent (outcome) variable being presence or absence of PD on the 
death certificate. Independent (predictor) variables eligible for inclusion in the model 
were gender (women [reference] vs. men), year of death (May 1, 1994 [reference] to 
September 30, 2001 vs. October 1, 2001 to May 1, 2007), and Hoehn and Yahr 
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stage (< 3 [reference] vs. ≥ 3). These analyses generated odds ratios (OR) with 95% 
confidence intervals (CI). 
 
RESULTS 
Of the 5,278 participants screened for neurological disorders at baseline (1994-
1995), we detected 81 prevalent PD cases, leaving 5,197 participants without 
baseline PD (Figure). Of these 5,197 participants, sufficient data were available on 
3,845 who completed the follow-up evaluation (1997–1998), including 30 incident 
cases of PD.[17, 18]  
To maximize the number of clinically diagnosed PD cases, we included data from 
the 30 incident cases as well as the 81 prevalent cases, even if some of the latter 
were not evaluated beyond the baseline assessment. Hence, the final sample of 
3,926 participants included 111 PD cases and 3,815 non-PD cases (Figure).  
The final sample of 3,926 participants was similar to the base sample of 5,278 
participants in terms of gender (2,268 [57.8%] vs. 3,040 [57.6%] women, chi-square 
= 0.03, p = 0.87), and education (523 [13.4%] vs. 711 [13.6%] illiterate, chi-square = 
5.42, p = 0.14), but it was, on average, 0.8 years younger (73.5 ± 6.6 vs. 74.3 ± 7.0 
years, t = 5.35, p < 0.001). 
The 3,926 participants had a mean duration of follow-up of 10.3 years 
(median = 12.6 years; range = 0.01 - 14.9 years). One-hundred-eleven (2.8%) of 
3,926 participants were diagnosed with PD (81 at baseline and 30 at the second 
evaluation). Baseline demographic characteristics are shown (Table 1). Subjects 
with PD differed from those without PD in terms of age, gender and geographic area 
(Table 1). 
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1,791 (45.6%) of 3,926 participants died over a median follow-up of 7.1 years 
(range 0.03–13.3 years), including 82 (73.9%) deaths among 111 participants with 
PD and 1,709 (44.8%) deaths among 3,815 participants without PD. 
Primary cause of death noted on the death certificates differed significantly by 
PD status (Table 2). PD was only rarely reported as the primary cause of death, 
even in the participants with PD (14.6%). In both groups, cardiovascular disease was 
the most frequently reported primary cause of death. Cancer was listed significantly 
less often in those with PD (14.6%) than in those without PD (24.2%). 
Participants with PD in whom PD was reported (N = 12) were similar in age to 
those in whom it was not (N = 70) (77.1 ± 5.9 vs. 77.4 ± 5.6 years, t = 0.15, p = 
0.878). They were also similar in gender (Chi Square test, p = 0.320). 
Of the 82 PD participants who died, 80 (97.6%) had information on Hoehn 
and Yahr stage. PD was listed in a similar proportion of those with Hoehn and Yahr 
stage ≥ 3 (7, 20.6%) vs. those with Hoehn and Yahr stage < 3 (5, 20.9%) (Fisher's 
exact test, p = 0.229). 
We divided our study period into two intervals, May 1, 1994 to September 30, 
2001 and October 1, 2001 to May 1, 2007; this cut-point produced a similar number 
of deaths in each time interval (889 and 902, respectively). The two time intervals 
were similar in terms of the proportion of PD patients who were reported on death 
certificates: 14.5% vs. 14.8%, Fisher's exact test, p = 0.974. 
 Age at death, gender, year of death, and Hoehn and Yahr stage were not 
significantly associated with reporting PD on death certificates (data not shown) in 
the stepwise multiple logistic regression model. There was no evidence of lack of fit 
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This is the first population-based study to investigate the validity of death 
certificates in terms of the listing of PD as a cause of death, which includes 
previously undiagnosed PD cases detected during the assessment. PD was reported 
in less than one-fifth (14.6%) of the certificates. This level of under-reporting is at the 
lower end of the range when compared with other studies that have examined the 
frequency of reporting PD on death certificates (20–70%).[9, 11-16] As noted above, 
prior studies,[9, 11-16] in not using a two-phase population-based are likely to have 
over-estimated validity. 
Our results are in line with prior community-based surveys or clinical series.[9, 
11-16] In a clinical series of 253 PD patients who were recruited from the Odense 
University Hospital in Denmark and died within a period of 18 years, 70% of the 
death certificates had PD as a diagnosis.[11] In one study involving one area of 
England and performed between 1966 and 1997, the authors showed that PD was 
recorded in death certificates of 130 (76%) of the 171 people (only 37% had PD 
coded as the underlying cause of death).[12] In a prospective community-based 
study involving 245 PD from a defined geographical area in Norway, 84 died in the 
period ranging from 1993 until Dec 31st 1996.[13] The death certificates showed that 
47 (56%) of the total of 84 deceased PD patients in the study cohort had PD listed as 
a cause of death.[13] In a series of 121 PD patients who were participating in a 
community-based study from a defined area of Sweden and died after 9.4 years of 
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follow-up, only 53% of the death certificates for the deceased patients recorded PD 
as an underlying or contributory cause of death.[14] In a national population-based 
survey from USA, among decedents with PD reported during life, 54.8% had PD 
recorded on the death certificate.[9] Nearly 70% of persons in higher income 
categories had PD recorded at death compared to 35.4% for those earning $10,000 
or less.[9] Age and gender adjusted odds of having PD recorded at death was 2.3 
(1.1-3.9) for those with an annual income of $35,000 or more.[9] In a prospective 
cohort of 143 PD patients under the care of the North Tyneside PD Service in UK, 
who died between January 1st 1999 and January 1st 2007, PD was recorded on the 
death certificate in 63% of patients.[15] Finally, in the 10-year follow-up data of the 
CamPaIGN study, death certificates indicated PD was a substantial contributor in 
only 20%.[16] 
It is beyond the scope of this article to determine if the trend of decreasing risk 
of mortality of PD in different publications and studies based on death certificates is 
due to a real biological change or whether it merely reflects changes in reporting 
over time.[6]  
The observation that cancer was listed significantly less often in those 
individuals with PD is of interest and is in line with the possible inverse occurrence of 
cancer and PD, similar to what has been noted for other conditions, such as 
cognitive impairment or Alzheimer’s disease disease.[34, 35] 
Our study has limitations. We did not collect data on the site of death and 
comorbidities at death, as well as data on who signed the death certificate (general 
physician vs. neurologist or geriatrician). It is logical to assume that the level of 
expertise of the physician signing the death certificate would impact upon the validity 
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of that certificate as in other neurodegenerative diseases, such as Alzheimer’s 
disease.[33, 36] In addition, competing mortality is an issue to consider – PD 
patients are at risk of developing dementia, and therefore a diagnosis of dementia 
could have been certified as the basic cause of death on death certificates in some 
subjects in decrement of a diagnosis of PD. This study also has several strengths, 
including the large number of participants and its population-based design. 
In conclusion, the results of the NEDICES study not only support those of 
previous studies,[9, 11, 13-16] but also reflect the need for a greater understanding 
and awareness by physicians, public health authorities, and other health 
management organs that PD should be considered as an important risk factor for 
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